WO2000068197A1 - 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS - Google Patents

3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS Download PDF

Info

Publication number
WO2000068197A1
WO2000068197A1 PCT/US2000/010981 US0010981W WO0068197A1 WO 2000068197 A1 WO2000068197 A1 WO 2000068197A1 US 0010981 W US0010981 W US 0010981W WO 0068197 A1 WO0068197 A1 WO 0068197A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
methylene
alkyl
halo
Prior art date
Application number
PCT/US2000/010981
Other languages
French (fr)
Inventor
Scott Dax
James Mcnally
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Priority to MXPA01011321A priority Critical patent/MXPA01011321A/en
Priority to AU46592/00A priority patent/AU4659200A/en
Priority to CA002373035A priority patent/CA2373035A1/en
Priority to EP00928340A priority patent/EP1177172A1/en
Publication of WO2000068197A1 publication Critical patent/WO2000068197A1/en
Priority to HK02102941.4A priority patent/HK1041263A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • This invention relates to a series of 3a,4,5,9b-tetrahydro-1 H-benz[e]indol-2-yl amine derivatives, pharmaceutical compositions containing them and intermediates used in their preparation.
  • the compounds of the invention are ligands for the neuropeptide Y Y5 (NPY5) receptor, a receptor which is associated with a number of central nervous system disorders and affective conditions.
  • the mammalian central nervous system is governed by a series of interdependent receptors, neurons, neurotransmitters, and proteins.
  • the neurons play a vital role in this system for, when externally or internally stimulated, they react by releasing neurotransmitters that bind to specific proteins.
  • neurotransmitters such as acetylcholine, adrenaline, norepinephrine, dopamine, serotonin, glutamate, and gamma-aminobutyric acid are well known, as are the specific receptors that recognize these compounds as ligands ("The Biochemical Basis of Neuropharmacology", Sixth Edition, Cooper, J. R.; Bloom, F. E.; Roth, R. H. Eds., Oxford University Press, New York, NY 1991 ).
  • neuropeptides play an integral role in neuronal operations.
  • Neuropeptides are now believed to be co-localized with perhaps more than one-half of the 100 billion neurons of the human central nervous system.
  • neuropeptides have been discovered in a number of animal species. In some instances the composition of these peptides is remarkably homogenous among species. This finding suggests that the function of neuropeptides is vital and has been impervious to evolutionary changes.
  • neuropeptides unlike small molecule neurotransmitters, are typically synthesized by the neuronal ribosome.
  • the active neuropeptides are produced as part of a larger protein which is enzymatically processed to yield the active substance. Based upon these differences, compared to small molecule neurotransmitters, neuropeptide- based strategies may offer novel therapies for CNS diseases and disorders. Specifically, agents that affect the binding of neuropeptides to their respective receptors or ameliorate responses that are mediated by neuropeptides are potentially useful in therapies for diseases associated with neuropeptides.
  • afflictions that are associated with the complex interdependent system of receptors and ligands within the central nervous system; these include neurodegenerative diseases, affective disorders such as anxiety, depression, pain and schizophrenia, and affective conditions that include a metabolic component, namely obesity.
  • Such conditions, disorders and diseases have been treated with small molecules and peptides which modulate neuronal responses to endogenous neurotransmitters.
  • NPY neuropeptide Y
  • NPY neuropeptide Y
  • PP pancreatic polypeptide family
  • Neuropeptide Y is a single peptide protein that consists of thirty-six amino acids containing an amidated C-terminus.
  • NPY has a distinctive conformation that consists of an N-terminal polyproline helical region and an amphiphilic ⁇ -helix joined by a characteristic PP- fold (Vladimir, S. et. Al. Biochemistry 1990, 20, 4509). Furthermore, NPY sequences from a number of animal species have been elucidated and all show a high degree of amino acid homology to the human protein (>94% in rat, dog, rabbit, pig, cow, sheep) (see Larhammar, D. in "The Biology of Neuropeptide Y and Related Peptides", Colmers, W. F. and Wahlestedt, C. Eds., Humana Press, Totowa, NJ 1993).
  • Endogenous receptor proteins that bind NPY and related peptides as ligands have been identified and distinguished, and several such proteins have been cloned and expressed.
  • Six different receptor subtypes [Y1 , Y2, Y3, Y4(PP), Y5, Y6 (formerly designated as a Y5 receptor)] are recognized today based upon binding profile, pharmacology and / or composition if identity is known (Wahlestedt, C. et. al. Ann. NY Acad. Sci. 1990, 611, 7; Larhammar, D. et. al. J. Biol. Chem. 1992, 267, 10935; Wahlestedt, C. et. al. Regul. Pept.
  • NPY receptor proteins belong to the family of so-called G-protein coupled receptors (GPCRs).
  • GPCRs G-protein coupled receptors
  • cAMP cyclic adenosine monophosphate
  • NPY inhibits forskolin-stimulated cAMP production / levels in a neuroblastoma cell line.
  • a Y5 ligand that mimics NPY in this fashion is an agonist whereas one that competitively reverses the NPY inhibition of forskolin-stimulated cAMP production is an antagonist.
  • Neuropeptide Y itself is the archetypal substrate for the NPY receptors and its binding can elicit a variety of pharmacological and biological effects in vitro and in vivo.
  • NPY When administered to the brain of live animals (intracerebroventricularly (icv) or into the amygdala), NPY produces anxiolytic effects in established animal models of anxiety such as the elevated plus-maze, Vogel punished drinking and Geller- Seifter's bar-pressing conflict paradigms (Hilor, M. et. al. Psychopharmacology 1989, 98, 524; Heilig, M. et. al. Reg. Peptides 1992, 41, 61 ; Heilig, M. et. al. Neuropsycho-pharmacology 1993, 8, 357).
  • compounds that mimic NPY are postulated to be useful for the treatment of anxiolytic disorders.
  • the immunoreactivity of neuropeptide Y is notably decreased in the cerebrospinal fluid of patients with major depression and those of suicide victims (Widdowson, P. S. et. al. Journal of Neurochemistry 1992, 59, 73), and rats treated with tricyclic antidepressants display significant increases of NPY relative to a control group (Hilor, M. et. al. European Journal of Pharmacology 1988, 147, 465). These findings suggest that an inadequate NPY response may play a role in some depressive illnesses, and that compounds that regulate the NPY-ergic system may be useful for the treatment of depression.
  • Neuropeptide Y improves memory and performance scores in animal models of learning (Flood, J. F. et. al. Brain Research 1987, 421, 280) and therefore may serve as a cognition enhancer for the treatment of neurodegenerative diseases such as Alzheimer's Disease (AD) as well as AIDS-related and senile dementia.
  • AD Alzheimer's Disease
  • Elevated plasma levels of NPY are present in animals and humans experiencing episodes of high sympathetic nerve activity such as surgery, newborn delivery and hemorrhage (Morris, M. J. et. al. Journal of Autonomic Nervous System
  • Neuropeptide Y also mediates endocrine functions such as the release of luteinizing hormone (LH) in rodents (Kalra, S. P. et. al. Frontiers in
  • Neuropeptide Y is a powerful stimulant of food intake; as little as one-billionth of a gram, when injected directly into the CNS, causes satiated rats to overeat (Clark, J. T. et. al. Endocrinology 1984, 115, 427; Levine, A. S. et. al. Peptides 1984, 5, 1025; Stanley, B. G. et. al. Life Sci. 1984, 35, 2635; Stanley, B. G. et. al. Proc. Nat. Acad. Sci. USA 1985, 82, 3940).
  • NPY is orexigenic in rodents but not anxiogenic when given intracerebroventricularly and so antagonism of neuropeptide receptors may be useful for the treatment of eating disorders such as obesity, anorexia nervosa and bulimia nervosa.
  • Y5 receptor rather than the classic Y1 receptor, is responsible for invoking NPY- stimulated food consumption in animals. It has been shown that the NPY fragment NPY2-36 is a potent inducer of feeding despite poor binding at the classic Y1 receptor (Stanley, B. G. et. al. Peptides 1992, 13, 581 ). Conversely, a potent and selective Y1 agonist has been reported to be inactive at stimulating feeding in animals (Kirby, D. A. et. al. J. Med. Chem. 1995, 38, 4579).
  • [D-Trp 32 ]NPY a selective Y5 receptor activator has been reported to stimulate food intake when injected into the hypothalamus of rats (Gerald, C. et. al. Nature 1996, 382, 168). Since [D-Trp 32 ]NPY appears to be a full agonist of the Y5 receptor with no appreciable Y1 activity, the Y5 receptor is hypothesized to be responsible for the feeding response. Accordingly compounds that antagonize the Y5 receptor should be effective in inhibiting food intake, particularly that stimulated by NPY.
  • arylsulfonamides that act as Y5 antagonists are known in the prior art.
  • PCT WO 97/19682 aryl sulfonamides and sulfamides derived from arylalkylamines are described as Y5 antagonists and are reported to reduce food consumption in animals.
  • PCT WO 97/20820 PCT WO 97/20822 and PCT WO 97/20823, sulfonamides containing heterocyclic systems such as quinazolin-2,4- diazirines, are likewise claimed as Y5 antagonists and reported to reduce feeding.
  • amide derivatives including those that contain a benzimidazolinone group are claimed to be neuropeptide Y receptor antagonists.
  • none of these compounds known in the prior art contain the amidine ring system present in the compounds of this invention.
  • the cyclic amidino sulfonamides and amidino benzimidazolinones and amidino arylpiperazines described in this application are novel molecular entities that may have binding motifs that are different from Y5 receptor ligands that have been disclosed in prior publications, and yet bind to a similar region of the Y5 receptor.
  • the compounds of this invention may also produce pharmacological and biological responses that are, in part or wholly, due to activation or antagonism of other Y receptor subtypes (e.g., Y1. Y2, Y4).
  • Y receptor subtypes e.g., Y1. Y2, Y4
  • the present invention is related to compounds of formula A
  • R is independently selected from the group consisting of hydrogen; hydroxy; halo; C ⁇ alkyl; C ⁇ alkoxy; substituted C, .8 alkyl wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo; substituted C ⁇ alkoxy wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo; trifluoroalkyl; C.,. 8 alkylthio and substituted C ⁇ alkylthio wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo, trifluoroalkyl and C ⁇ alkoxy; C 3 .
  • B 2 is selected from the group consisting of hydrogen; C ⁇ alkyl; substituted C ⁇ alkyl wherein the substituent is halo;
  • B 2 may have either a cis- or trans- stereochemical orientation with respect to B ⁇ both enantiomers of each diastereomeric set are part of the present invention
  • L is selected from the group consisting of
  • R 2 is independently selected from the group consisting of hydrogen; C,_ 5 alkyl; substituted C ⁇ alkyl wherein the substituent is halo;
  • B. may have either a cis- or trans- stereochemical orientation with respect to B 2 ; both enantiomers of each diastereomeric set are part of this invention.
  • Z is selected from the group consisting of:
  • R 3 is independently selected from the group consisting of C ⁇ alkyl; substituted C ⁇ alkyl wherein the substituent is selected from C,_ 8 alkoxy and halo; cycloalkyl; substituted cycloalkyl wherein the substituent is selected from C ⁇
  • R 4 is independently selected from the group consisting of C,. 8 alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C ⁇ alkyl wherein the substituent is halo;
  • n 0-2;
  • L is C ⁇ alkylene, C 2 . 10 alkenylene, C 2 . 10 alkynylene, C 3 . 7 cycloalkylene, or (N-methylene)piperidin-4-yl,
  • Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1 H-benzimidazol-1 -yl;
  • Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
  • alkyl and alkoxy whether used alone or as part of a substituent group, include straight and branched chains having 1-8 carbon atoms.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, f-butyl, pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2- methylbutyl, neopentyl, hexyl, 1-methylpentyl, 3-methylpentyl.
  • Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups.
  • aryl is intended to include phenyl and naphthyl.
  • halo unless otherwise indicated, includes bromo, chloro, fluoro and iodo.
  • the term “halo" includes bromo, chloro, fluoro and iodo.
  • cycloalkyl is intended to include cycloalkyl groups having 3-7 carbon atoms.
  • substituents the term “independently” means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
  • Those compounds of the present invention which contain a basic moiety can be converted to the corresponding acid addition salts by techniques known to those skilled in the art.
  • Suitable acids which can be employed for this purpose include hydrochloric, hydrobromic, hydnodic, perchloric, sulfuhc, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, or saccharin, and the like.
  • the acid addition salts can be prepared by reacting the free base of compounds of formula A with the acid and isolating the salt.
  • compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral).
  • suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like;
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate the major site of absorption.
  • the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation.
  • injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
  • the daily dose of the active ingredient to be administered will depend on the age of the patient in need of such treatment, the particular condition to be treated and the manner of administration. Generally, an approximate daily dose of about 10 to about 500 mg is to be administered depending upon the mode of administration and the weight of the patient being treated. Determination of the optimum doses and frequency of administration for a particular disease state or disorder is within the experimental capabilities of those knowledgeable of the specific disease or disorder being treated.
  • the pharmaceutical compositions described herein will typically contain from about 1 to about 1000 mg of the active ingredient per dosage; one or more doses per day may be administered. Determination of optimum doses and frequency of dosing for a particular disease state or disorder is within the experimental capabilities of those knowledgeable in the treatment of central nervous system disorders. The preferred dose range is from about 1-100 mg/kg.
  • the compounds of Formula A are useful for treating feeding disorders such as obesity, anorexia nervosa and bulimia nervosa, and abnormal conditions such as epilepsy, depression, anxiety, sleeping disorders, dyspilipidimia, diabetes, hypertension, migraine, pain and sexual / reproductive disorders in which modulation of the NPY5 receptor may be useful.
  • the compounds compete with the endogenous ligand PYY and possibly NPY and possibly non-endogenous ligands as well, and bind to the NPY5 receptor.
  • the compounds demonstrate antagonist activity by antagonizing the action of NPY upon binding to the Y5 receptor.
  • the compounds described herein are ligands of the NPY5 receptor, but are not necessarily limited solely in their pharmacological or biological action due to binding to this or any neuropeptide, neurotransmitter or G-protein coupled receptor.
  • the described compounds may also undergo binding to dopamine or serotonin receptors.
  • the compounds described herein are potentially useful in the regulation of metabolic and endocrine functions, particularly those associated with feeding, and as such, may be useful for the treatment of obesity.
  • the compounds described herein are potentially useful for modulating other endocrine functions, particularly those controlled by the pituitary and hypothalamic glands, and therefore may be useful for the treatment of inovulation/infertility due to insufficient release of luteinizing hormone (LH).
  • LH luteinizing hormone
  • the present invention comprises pharmaceutical compositions containing one or more of the compounds of Formula A.
  • R.,, R 2 , B 1 ( B 2 , Y, n, L and Z are defined as above.
  • the present invention comprises intermediates used in the manufacture of these compounds. Examples of preferred compounds of formula A include:
  • each synthetic route consists of several sequential chemical operations which are outlined in Schemes 1-8 and which can be generalized as described below:
  • the respective product of each process step be separated from other components of the reaction mixture and subjected to purification before its use as a starting material in a subsequent step.
  • Separation techniques typically include evaporation, extraction, precipitation and filtration.
  • Purification techniques typically include column chromatography (Still, W. C. et. al., J. Org. Chem. 1978, 43, 2921 ), thin-layer chromatography, crystallization and distillation.
  • the structures of the final products, intermediates and starting materials are confirmed by spectroscopic, spectrometric and analytical methods including nuclear magnetic resonance (NMR), mass spectrometry (MS) and liquid chromatography (HPLC).
  • ethyl ether, tetrahydrofuran and dioxane are common examples of an ethereal solvent; benzene, toluene, hexanes and cyclohexane are typical hydrocarbon solvents and dichloromethane and dichloroethane are representative halohydrocarbon solvents.
  • the free base is obtained by techniques known to those skilled in the art.
  • an appropriately substituted ⁇ -tetralone (I) is reacted with a secondary amine such as pyrrolidine in an inert halohydrocarbon solvent such as, for example, dichloromethane or a hydrocarbon solvent such as benzene for example, under Dean-Stark conditions (removal of water) or in an ethereal solvent such as tetrahydrofuran or an alcohol solvent such as methanol, at a temperature ranging from ambient temperature to reflux, to afford enamine (II).
  • a secondary amine such as pyrrolidine
  • an inert halohydrocarbon solvent such as, for example, dichloromethane or a hydrocarbon solvent such as benzene for example
  • Dean-Stark conditions removal of water
  • an ethereal solvent such as tetrahydrofuran or an alcohol solvent such as methanol
  • Cyanomethylation of enamine (II) is accomplished by reaction with an ⁇ - haloacetonitrile, such as bromoacetonitrile, in an inert solvent such as acetonitrile, at a temperature ranging from ambient temperature to reflux, to afford the iminium salt (III).
  • the iminium salt is hydrolyzed by treatment with an aqueous acid solution, such as hydrochloric or acetic acid, which may contain an organic solvent such as an alcohol or dioxane to facilitate dissolution and reaction, to afford the ⁇ - cyanomethyl- ⁇ -tetralone (IV).
  • Reductive amination and concomitant cyclization of tetralone (IV) is accomplished by reaction with a reducing agent such as, for example, sodium cyanoborohydride, and an ammonium equivalent such as, for example, ammonium acetate, in an alcohol solvent such as methanol or in a halohydrocarbon solvent such as dichloromethane, at a temperature ranging from ambient temperature to reflux.
  • a reducing agent such as, for example, sodium cyanoborohydride, and an ammonium equivalent such as, for example, ammonium acetate
  • an alcohol solvent such as methanol or in a halohydrocarbon solvent such as dichloromethane
  • An organic acid such as acetic acid for example, may be added to facilitate this transformation; cyclization under these reaction conditions typically affords the c/s-amidine (V) as the major product.
  • Amidine (V) may be converted to its acid addition salt upon treatment with organic acids such as trifluoroacetic acid, or via treatment with inorganic acids such as hydrochloric acid, to afford the corresponding amidine salt (VI) (Scheme 1 ).
  • HX in Scheme 1 represents the hydrochloride salt.
  • amidine products described above ((V) and (VI)) are acylated via suitable amidation methods (see Gross and Meienhofer, Eds., "The Peptides", Vols. 1-3, Academic Press, New York, NY, 1979-1981 ).
  • a carboxylic acid is converted to an activated ester via peptide coupling methods known to those skilled in the art, and the product of this reaction is subsequently reacted with amidine (V) or (VI) to afford the corresponding amide product.
  • a sulfonamido-carboxylic acid is first treated with an amine base, such as triethylamine, in an inert hydrocarbon, ethereal or halohydrocarbon solvent, such as dichloroethane, and subsequently reacted with isobutyl chloroformate at a temperature from about -20°C to 80°C.
  • an amine base such as triethylamine
  • an inert hydrocarbon, ethereal or halohydrocarbon solvent such as dichloroethane
  • a suitable reducing agent such as borane-tetrahydrofuran complex or lithium aluminum hydride in an inert hydrocarbon solvent such as toluene or ethereal solvent such as tetrahydrofuran, at a temperature from ambient temperature to reflux.
  • the crude product is treated with an aqueous acid solution such as hydrochloric acid (3M-6M) in order to cleave any boron complexes; neutralization affords sulfonamides (XI) and (XII) as corresponding free bases.
  • 4-(2-keto-1- benzimidazolinyl)piperidine is reacted with a bromoacetic acid ester, such as ethyl bromoacetate, in the presence of an amine base, such as diisopropylethylamine, in an inert solvent such as acetonitnle, at a temperature ranging from ambient temperature to reflux, to afford ethyl [4-(2-keto-1-benzimidazolinyl)piperidin-1- yljacetate.
  • a bromoacetic acid ester such as ethyl bromoacetate
  • an amine base such as diisopropylethylamine
  • an inert solvent such as acetonitnle
  • This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an alcoholic solution such as aqueous methanol, to yield, upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, [4-(2-keto-1-benzimidazolinyl)piperidin-1- yljacetic acid.
  • This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an aqueous methanol, to yield, upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, (4-arylpiperazin-1-yl)acetic acid.
  • peptide coupling e.g. HBTU
  • base such as triethylamine
  • [RED] e.g., BH 3 -THF
  • This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an alcoholic solution such as aqueous methanol, to yield upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, (1-aryl-1 ,3,8-triazaspiro-[4,5]decan-4-one-8-yl)acetic acid.
  • an alcoholic solution such as aqueous methanol
  • Examples include masking an amine group as a carbamate, amide or phthalamide, and masking an hydroxyl group as an ether or ester.
  • Other R, substituents are available through (other) functional group manipulations such as, for example, reduction of a nitro group to an amine or dehydration of an amide to a nitrile.
  • alkylsulfonyl and cycloalkylsulfonyl halides can be used to prepare sulfonamides of formula A in which the R 3 substituent is alkyl or cycloalkyl respectively.
  • the solution was stirred for 30 min at 0°C.
  • the solvents were evaporated in vacuo, and the residue was purified by preparative HPLC on C 18 reverse phase column, using water/acetonitrile/t fluoroacetic acid (50:50:0.1 ) as the eluent.
  • the product obtained was dissolved in a minimum amount of methanol and converted to the hydrochloride salt by treatment with ethanolic hydrogen chloride.
  • the resultant mixture was stirred at 0°C for 1 h, and stirring was continued at room temperature for an additional 1 h.
  • the mixture was cooled on an ice bath and methanol was added. After stirring for several minutes, the solvents were evaporated in vacuo.
  • the residue was purified by preparative HPLC on a C18 reverse phase column, eluted with water/acetonitrile/trifluoroacetic acid (-50:50:0.1 ). The product was dissolved in a minimum amount of methanol and converted to the hydrochloride salt with ethanolic hydrogen chloride.
  • the compounds described in this invention were evaluated for binding to the human neuropeptide Y5 receptor.
  • the human NPY5 receptor cDNA (Genbank Accession number U66275) was inserted into the vector pClneo (Invitrogen) and transfected into human embryonic kidney cells (HEK-293) via calcium phosphate method (Cullen 1987). Stably transfected cells were selected with G-418 (600 ⁇ g/mL). Stably transfected cells served as the source for the membranes for the NPY5 receptor binding assay.
  • NPY5-transfected HEK293 cells were grown to confluence in 150 cm 2 culture dishes. Cells were washed once with phosphate-buffered saline (Gibco Cat# 14040-133). Cells were then incubated in phosphate-buffered saline without calcium and without magnesium, supplemented with 2 mM EDTA. Cells were incubated for 10 minutes at room temperature and the cells were collected by repetitive pipeting. Cells were formed into pellets and then frozen at -80°C until needed. Frozen pellets were homogenized with a polytron at full speed for 12 seconds in a homogenization buffer (20 mM Tris HCI, 5 mM EDTA, pH 7.4).
  • a competition binding assay known to those skilled in the art, was used in which compounds of formula A compete with 25 I-PYY for binding to cell membranes.
  • the less 125 I-PYY bound to the membranes implies that a compound is a good inhibitor (competitor).
  • Bound 5 I-PYY is determined by centrifugation of membranes, aspirating supernatant, washing away residual 125 l- PYY and subsequently counting the bound sample in a g-counter.
  • Compounds to be tested were prepared as 10x stocks in binding buffer and added first to assay tubes (RIA vials, Sarstedt). Twenty (20) ⁇ L of each 10x compound stock is pipeted into vials and 80 ⁇ L of 125 I-PYY (NEN catalog number NEX240), which has been diluted to a concentration of 200 pM in 0.25 % BSA in binding buffer, is added to the compound tubes (final concentration of 25 I-PYY is 80 pM). To each tube is added 100 ⁇ L of membranes and the mixture is agitated by pipeting 2 times. Samples are incubated for 1 hr at room temperature.
  • Aluminum cast plates (Sarstedt) containing the vials are then centrifuged 10 minutes at 3200 rpm in a Sorvall RT6000. Supernatant is then aspirated. To each vial 400 ⁇ L PBS is added and this is then aspirated again. Vials are then put in carrier polypropylene 12x75 tube and counted in gamma counter (Packard). Non-specific binding is determined in the presence of 300 nM NPY. Percent inhibition of 125 I-PYY binding is calculated by subtracting non-specific binding from the test samples (compound (I)), taking these counts and dividing by total binding, and multiplying by 100.
  • Inhibitory concentration values (IC 50 ) of compounds that show appreciable inhibition of 125 l- PYY binding are calculated by obtaining percent inhibition of 125 I-PYY binding values at different concentrations of the test compound, and using a graphing program such as GraphPad Prism (San Diego, CA) to calculate the concentration of test compound that inhibits fifty-percent of 125 I-PYY binding (Table 4).
  • Binding Affinities of Compounds of Formula A for the Human NPY Y5 Receptor (expressed as % Inhibition of 125 I-PYY Binding)
  • Male Long-Evans rats (180-200 grams) are housed individually and are maintained on a once-a-day feeding schedule (i.e., 10 a.m. until 4 p.m.) for five days following quarantine to allow the animals to acclimate to feeding on powdered chow (#5002 PMI Certified Rodent Meal) during the allotted time.
  • the chow is made available in an open jar, anchored in the cage by a wire, with a metal follower covering the food to minimize spillage. Water is available ad-libitum.
  • Animals are fasted for 18 hours prior to testing. At the end of the fasting period, animals are administered either compounds of the invention or vehicle. Vehicle and test compounds are administered either orally (5 mL/kg) 60 minutes prior to the experiment, or 30 minutes prior when given subcutaneously (1 mL/kg) or intraperitoneally (1 mL/kg).
  • Compounds of the invention are administered orally as a suspension in aqueous 0.5% methylcellulose-0.4% Tween 80, or intraperitoneally as a solution or suspension in PEG 200; compound concentrations typically range from 1 mg/kg to 100 mg/kg, preferably from 10-30 mg/kg.
  • Food intake is measured at 2, 4, and 6 hours after administration by weighing the special jar containing the food before the experiment and at the specified times. Upon completion of the experiment, all animals are given a one-week washout period before retesting.
  • Percent reduction of food consumption is calculated subtracting the grams of food consumed by the treated group from the grams of food consumed by the control group divided by the grams of food consumed by the control group, multiplied by 100. A negative value indicates a reduction in food consumption and a positive value indicates an increase in food consumption.
  • Vehicle PEG-2000 N 8 10.19 g 13.71 g 21.03 g 10.84 g
  • Vehicle PEG-2000 N 8 9.13 g 12.75 g 21.25 g 12.13 g

Abstract

Compounds of formula: (A) are disclosed as ligands for neuropeptide Y receptors and as such are useful in the treatment of obesity and disorders of the central nervous system.

Description

3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED
NEUROPEPTIDE Y RECEPTORS LIGANDS
USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
This is a non-provisional of Application Serial No. 60/132,660, filed May 5,
1999. FIELD OF THE INVENTION
This invention relates to a series of 3a,4,5,9b-tetrahydro-1 H-benz[e]indol-2-yl amine derivatives, pharmaceutical compositions containing them and intermediates used in their preparation. The compounds of the invention are ligands for the neuropeptide Y Y5 (NPY5) receptor, a receptor which is associated with a number of central nervous system disorders and affective conditions.
BACKGROUND OF THE INVENTION
Regulation and function of the mammalian central nervous system is governed by a series of interdependent receptors, neurons, neurotransmitters, and proteins. The neurons play a vital role in this system for, when externally or internally stimulated, they react by releasing neurotransmitters that bind to specific proteins. Common examples of endogenous small molecule neurotransmitters such as acetylcholine, adrenaline, norepinephrine, dopamine, serotonin, glutamate, and gamma-aminobutyric acid are well known, as are the specific receptors that recognize these compounds as ligands ("The Biochemical Basis of Neuropharmacology", Sixth Edition, Cooper, J. R.; Bloom, F. E.; Roth, R. H. Eds., Oxford University Press, New York, NY 1991 ).
In addition to the endogenous small molecule neurotransmitters, there is increasing evidence that neuropeptides play an integral role in neuronal operations. Neuropeptides are now believed to be co-localized with perhaps more than one-half of the 100 billion neurons of the human central nervous system. In addition to humans, neuropeptides have been discovered in a number of animal species. In some instances the composition of these peptides is remarkably homogenous among species. This finding suggests that the function of neuropeptides is vital and has been impervious to evolutionary changes. Furthermore, neuropeptides, unlike small molecule neurotransmitters, are typically synthesized by the neuronal ribosome. In some cases, the active neuropeptides are produced as part of a larger protein which is enzymatically processed to yield the active substance. Based upon these differences, compared to small molecule neurotransmitters, neuropeptide- based strategies may offer novel therapies for CNS diseases and disorders. Specifically, agents that affect the binding of neuropeptides to their respective receptors or ameliorate responses that are mediated by neuropeptides are potentially useful in therapies for diseases associated with neuropeptides.
There are a number of afflictions that are associated with the complex interdependent system of receptors and ligands within the central nervous system; these include neurodegenerative diseases, affective disorders such as anxiety, depression, pain and schizophrenia, and affective conditions that include a metabolic component, namely obesity. Such conditions, disorders and diseases have been treated with small molecules and peptides which modulate neuronal responses to endogenous neurotransmitters.
One example of the class of neuropeptides is neuropeptide Y (NPY). NPY was first isolated from porcine brain (Tatemoto, K. et al. Nature 1982, 296, 659) and was shown to be structurally similar to other members of the pancreatic polypeptide (PP) family such as peptide YY, which is primarily synthesized by endocrine cells in the gut, and pancreatic polypeptide, which is synthesized by the pancreas. Neuropeptide Y is a single peptide protein that consists of thirty-six amino acids containing an amidated C-terminus. Like other members of the pancreatic polypeptide family, NPY has a distinctive conformation that consists of an N-terminal polyproline helical region and an amphiphilic α-helix joined by a characteristic PP- fold (Vladimir, S. et. Al. Biochemistry 1990, 20, 4509). Furthermore, NPY sequences from a number of animal species have been elucidated and all show a high degree of amino acid homology to the human protein (>94% in rat, dog, rabbit, pig, cow, sheep) (see Larhammar, D. in "The Biology of Neuropeptide Y and Related Peptides", Colmers, W. F. and Wahlestedt, C. Eds., Humana Press, Totowa, NJ 1993).
Endogenous receptor proteins that bind NPY and related peptides as ligands have been identified and distinguished, and several such proteins have been cloned and expressed. Six different receptor subtypes [Y1 , Y2, Y3, Y4(PP), Y5, Y6 (formerly designated as a Y5 receptor)] are recognized today based upon binding profile, pharmacology and / or composition if identity is known (Wahlestedt, C. et. al. Ann. NY Acad. Sci. 1990, 611, 7; Larhammar, D. et. al. J. Biol. Chem. 1992, 267, 10935; Wahlestedt, C. et. al. Regul. Pept. 1986, 13, 307; Fuhlendorff, J. U. et. al. Proc. Natl. Acad. Sci. USA 1990, 87, 182; Grundemar, L. et. al. J. Pharmacol. Exp. Ther. 1991 , 258, 633; Laburthe, M. et. al. Endocrinology 1986, 118, 1910; Castan, I. et. al. Endocrinology 1992, 131, 1970; Gerald, C. et. al. Nature 1996, 382, 168; Weinberg, D. H. et. al. Journal of Biological Chemistry 1996, 271, 16435; Gehlert, D. et. al. Current Pharmaceutical Design 1995, 1, 295; Lundberg, J. M. et. al. Trends in Pharmaceutical Sciences 1996, 17, 301 ). Most and perhaps all NPY receptor proteins belong to the family of so-called G-protein coupled receptors (GPCRs). The neuropeptide Y5 receptor, a putative GPCR, is negatively coupled to cellular cyclic adenosine monophosphate (cAMP) levels via the action of adenylate cyclase (Gerald, C. et. al. Nature 1996, 382, 168; Gerald, C. et. al. PCT WO 96/16542). For example, NPY inhibits forskolin-stimulated cAMP production / levels in a neuroblastoma cell line. A Y5 ligand that mimics NPY in this fashion is an agonist whereas one that competitively reverses the NPY inhibition of forskolin-stimulated cAMP production is an antagonist.
Neuropeptide Y itself is the archetypal substrate for the NPY receptors and its binding can elicit a variety of pharmacological and biological effects in vitro and in vivo. When administered to the brain of live animals (intracerebroventricularly (icv) or into the amygdala), NPY produces anxiolytic effects in established animal models of anxiety such as the elevated plus-maze, Vogel punished drinking and Geller- Seifter's bar-pressing conflict paradigms (Heilig, M. et. al. Psychopharmacology 1989, 98, 524; Heilig, M. et. al. Reg. Peptides 1992, 41, 61 ; Heilig, M. et. al. Neuropsycho-pharmacology 1993, 8, 357). Thus compounds that mimic NPY are postulated to be useful for the treatment of anxiolytic disorders.
The immunoreactivity of neuropeptide Y is notably decreased in the cerebrospinal fluid of patients with major depression and those of suicide victims (Widdowson, P. S. et. al. Journal of Neurochemistry 1992, 59, 73), and rats treated with tricyclic antidepressants display significant increases of NPY relative to a control group (Heilig, M. et. al. European Journal of Pharmacology 1988, 147, 465). These findings suggest that an inadequate NPY response may play a role in some depressive illnesses, and that compounds that regulate the NPY-ergic system may be useful for the treatment of depression.
Neuropeptide Y improves memory and performance scores in animal models of learning (Flood, J. F. et. al. Brain Research 1987, 421, 280) and therefore may serve as a cognition enhancer for the treatment of neurodegenerative diseases such as Alzheimer's Disease (AD) as well as AIDS-related and senile dementia.
Elevated plasma levels of NPY are present in animals and humans experiencing episodes of high sympathetic nerve activity such as surgery, newborn delivery and hemorrhage (Morris, M. J. et. al. Journal of Autonomic Nervous System
1986, 17, 143). Thus chemical substances that alter the NPY-ergic system may be useful for alleviating the condition of stress.
Neuropeptide Y also mediates endocrine functions such as the release of luteinizing hormone (LH) in rodents (Kalra, S. P. et. al. Frontiers in
Neuroendrocrinology 1992, 13, 1 ). Since LH is vital for mammalian ovulation, a compound that mimics the action of NPY could be useful for the treatment of infertility, particularly in women with so-called luteal phase defects.
Neuropeptide Y is a powerful stimulant of food intake; as little as one-billionth of a gram, when injected directly into the CNS, causes satiated rats to overeat (Clark, J. T. et. al. Endocrinology 1984, 115, 427; Levine, A. S. et. al. Peptides 1984, 5, 1025; Stanley, B. G. et. al. Life Sci. 1984, 35, 2635; Stanley, B. G. et. al. Proc. Nat. Acad. Sci. USA 1985, 82, 3940). Thus NPY is orexigenic in rodents but not anxiogenic when given intracerebroventricularly and so antagonism of neuropeptide receptors may be useful for the treatment of eating disorders such as obesity, anorexia nervosa and bulimia nervosa.
In recent years, a variety of potent, structurally distinct small molecule Y1 antagonists has been discovered and developed (Hipskind, P. A. et. al. Annu. Rep. Med. Chem. 1996, 31, 1-10; Rudolf, K. et. al. Eur. J. Pharmacol. 1994, 271, R11 ; Serradeil-Le Gal, C. et. al. FEBS Lett. 1995, 362, 192; Wright, J. et. al. Bioorg. Med. Chem. Lett. 1996, 6, 1809; Poindexter, G. S. et. al. United States Patent 5,668,151 ; Peterson, J. M. et. al. WO9614307 (1996)). However, despite claims of activity in rodent models of feeding, it is unclear if inhibition of a feeding response can be solely attributed to antagonism of the Y1 receptor.
Several landmark studies suggest that an "atypical Y1 " receptor and / or the
Y5 receptor, rather than the classic Y1 receptor, is responsible for invoking NPY- stimulated food consumption in animals. It has been shown that the NPY fragment NPY2-36 is a potent inducer of feeding despite poor binding at the classic Y1 receptor (Stanley, B. G. et. al. Peptides 1992, 13, 581 ). Conversely, a potent and selective Y1 agonist has been reported to be inactive at stimulating feeding in animals (Kirby, D. A. et. al. J. Med. Chem. 1995, 38, 4579). More pertinent to the invention described herein, [D-Trp32]NPY, a selective Y5 receptor activator has been reported to stimulate food intake when injected into the hypothalamus of rats (Gerald, C. et. al. Nature 1996, 382, 168). Since [D-Trp32]NPY appears to be a full agonist of the Y5 receptor with no appreciable Y1 activity, the Y5 receptor is hypothesized to be responsible for the feeding response. Accordingly compounds that antagonize the Y5 receptor should be effective in inhibiting food intake, particularly that stimulated by NPY.
Certain arylsulfonamides that act as Y5 antagonists are known in the prior art. In PCT WO 97/19682, aryl sulfonamides and sulfamides derived from arylalkylamines are described as Y5 antagonists and are reported to reduce food consumption in animals. In PCT WO 97/20820, PCT WO 97/20822 and PCT WO 97/20823, sulfonamides containing heterocyclic systems such as quinazolin-2,4- diazirines, are likewise claimed as Y5 antagonists and reported to reduce feeding. In WO 98/35957, various amide derivatives, including those that contain a benzimidazolinone group are claimed to be neuropeptide Y receptor antagonists. However, none of these compounds known in the prior art contain the amidine ring system present in the compounds of this invention. The cyclic amidino sulfonamides and amidino benzimidazolinones and amidino arylpiperazines described in this application are novel molecular entities that may have binding motifs that are different from Y5 receptor ligands that have been disclosed in prior publications, and yet bind to a similar region of the Y5 receptor. In addition to exhibiting an affinity for the neuropeptide Y5 receptor, the compounds of this invention may also produce pharmacological and biological responses that are, in part or wholly, due to activation or antagonism of other Y receptor subtypes (e.g., Y1. Y2, Y4).
SUMMARY OF THE INVENTION
The present invention is related to compounds of formula A
Figure imgf000008_0001
in which
R, is independently selected from the group consisting of hydrogen; hydroxy; halo; C^alkyl; C^alkoxy; substituted C,.8 alkyl wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo; substituted C^ alkoxy wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo; trifluoroalkyl; C.,.8alkylthio and substituted C^alkylthio wherein the substituent is selected from halo, such as chloro, bromo, fluoro and iodo, trifluoroalkyl and C^alkoxy; C3.6cycloalkyl; C3_8cycloalkyloxy; nitro; amino; C^alkylamino; C^dialkylamino; C4.8cycloalkylamino; cyano; carboxy; C^alkylcarbonyloxy; C,.5alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl wherein the substitutent is selected from halo, hydroxyl, nitro, amino and cyano;
is 0-2;
B2 is selected from the group consisting of hydrogen; C^alkyl; substituted C^alkyl wherein the substituent is halo;
B2 may have either a cis- or trans- stereochemical orientation with respect to B^ both enantiomers of each diastereomeric set are part of the present invention;
Y is methylene (-CH2-) or carbonyl (C=O)
L is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3_7cycloalkylene; C^cycloalkylC^alkylene; arylC^alkylene; (N-methylene)piperidin-4-yl;
\ — CH2— N ) 1
(N-methylene)piperazin-4-yl;
/~
;H — N N-
and (N-methylene)piperidin-4,4-diyl;
Figure imgf000009_0001
R2 is independently selected from the group consisting of hydrogen; C,_5alkyl; substituted C^alkyl wherein the substituent is halo;
B., is hydrogen;
B., may have either a cis- or trans- stereochemical orientation with respect to B2; both enantiomers of each diastereomeric set are part of this invention.
Z is selected from the group consisting of:
phenyl;
Figure imgf000010_0001
N-sulfonamido;
Figure imgf000010_0002
N-(aryl)sulfonamido;
Figure imgf000010_0003
2,3-dihydro-2-oxo-1 /-/-benzimidazol-1 -yl;
Figure imgf000010_0004
and 1 -aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
Figure imgf000011_0001
R3 is independently selected from the group consisting of C^alkyl; substituted C^alkyl wherein the substituent is selected from C,_8alkoxy and halo; cycloalkyl; substituted cycloalkyl wherein the substituent is selected from C^
8alkoxy and halo; naphthyl; substituted naphthyl wherein the substituent is selected from halo, nitro, amino and cyano; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl wherein the substituent is selected from halo, nitro, amino and cyano;
R4 is independently selected from the group consisting of C,.8alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C^alkyl wherein the substituent is halo;
m is 0-2;
and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof,
with the following provisions:
when L is C^alkylene, C2.10alkenylene, C2.10alkynylene, C3.7cycloalkylene,
Figure imgf000011_0002
or (N-methylene)piperidin-4-yl,
then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1 H-benzimidazol-1 -yl;
when L is (N-methylene)piperazin-4-yl, then Z is phenyl or naphthyl;
and when L is (N-methylene)piperidin-4,4,-diyl;
then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
As used herein unless otherwise noted the terms "alkyl" and "alkoxy" whether used alone or as part of a substituent group, include straight and branched chains having 1-8 carbon atoms. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, f-butyl, pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2- methylbutyl, neopentyl, hexyl, 1-methylpentyl, 3-methylpentyl. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. The term "aryl" is intended to include phenyl and naphthyl. The term "halo", unless otherwise indicated, includes bromo, chloro, fluoro and iodo. The term
"cycloalkyl" is intended to include cycloalkyl groups having 3-7 carbon atoms. With reference to substituents, the term "independently" means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
Those compounds of the present invention which contain a basic moiety can be converted to the corresponding acid addition salts by techniques known to those skilled in the art. Suitable acids which can be employed for this purpose include hydrochloric, hydrobromic, hydnodic, perchloric, sulfuhc, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, or saccharin, and the like. In general, the acid addition salts can be prepared by reacting the free base of compounds of formula A with the acid and isolating the salt.
Pharmaceutical compositions containing one or more of the compounds of the invention described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate the major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.
The daily dose of the active ingredient to be administered will depend on the age of the patient in need of such treatment, the particular condition to be treated and the manner of administration. Generally, an approximate daily dose of about 10 to about 500 mg is to be administered depending upon the mode of administration and the weight of the patient being treated. Determination of the optimum doses and frequency of administration for a particular disease state or disorder is within the experimental capabilities of those knowledgeable of the specific disease or disorder being treated.
For the treatment of disorders of the central nervous system, the pharmaceutical compositions described herein will typically contain from about 1 to about 1000 mg of the active ingredient per dosage; one or more doses per day may be administered. Determination of optimum doses and frequency of dosing for a particular disease state or disorder is within the experimental capabilities of those knowledgeable in the treatment of central nervous system disorders. The preferred dose range is from about 1-100 mg/kg. As modulators of the NPY5 receptor, the compounds of Formula A are useful for treating feeding disorders such as obesity, anorexia nervosa and bulimia nervosa, and abnormal conditions such as epilepsy, depression, anxiety, sleeping disorders, dyspilipidimia, diabetes, hypertension, migraine, pain and sexual / reproductive disorders in which modulation of the NPY5 receptor may be useful. The compounds compete with the endogenous ligand PYY and possibly NPY and possibly non-endogenous ligands as well, and bind to the NPY5 receptor. In addition, the compounds demonstrate antagonist activity by antagonizing the action of NPY upon binding to the Y5 receptor.
The compounds described herein are ligands of the NPY5 receptor, but are not necessarily limited solely in their pharmacological or biological action due to binding to this or any neuropeptide, neurotransmitter or G-protein coupled receptor. For example, the described compounds may also undergo binding to dopamine or serotonin receptors. The compounds described herein are potentially useful in the regulation of metabolic and endocrine functions, particularly those associated with feeding, and as such, may be useful for the treatment of obesity. In addition, the compounds described herein are potentially useful for modulating other endocrine functions, particularly those controlled by the pituitary and hypothalamic glands, and therefore may be useful for the treatment of inovulation/infertility due to insufficient release of luteinizing hormone (LH).
The present invention comprises pharmaceutical compositions containing one or more of the compounds of Formula A.
Figure imgf000014_0001
wherein R.,, R2, B1 ( B2, Y, n, L and Z are defined as above. In addition, the present invention comprises intermediates used in the manufacture of these compounds. Examples of preferred compounds of formula A include:
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
20
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
25 DETAILED DESCRIPTION OF THE INVENTION
The cyclic amidines of formula A that comprise this invention are synthesized via several distinct chemical syntheses which are described in detail in the
Examples set forth below. In general, each synthetic route consists of several sequential chemical operations which are outlined in Schemes 1-8 and which can be generalized as described below:
• Introduction of the α-cyanomethyl group onto a β-tetralone nucleus.
• Concomitant reductive amination / cyclization to produce amidine intermediates.
• Acylation of cyclic amidine intermediates to afford compounds of formula A in which Y = carbonyl (C=O).
• Reduction of the amide to generate the cyclic amidines of formula A in which Y = methylene (-CH2-).
It is generally preferred that the respective product of each process step be separated from other components of the reaction mixture and subjected to purification before its use as a starting material in a subsequent step. Separation techniques typically include evaporation, extraction, precipitation and filtration. Purification techniques typically include column chromatography (Still, W. C. et. al., J. Org. Chem. 1978, 43, 2921 ), thin-layer chromatography, crystallization and distillation. The structures of the final products, intermediates and starting materials are confirmed by spectroscopic, spectrometric and analytical methods including nuclear magnetic resonance (NMR), mass spectrometry (MS) and liquid chromatography (HPLC). In the descriptions for the preparation of compounds of this invention, ethyl ether, tetrahydrofuran and dioxane are common examples of an ethereal solvent; benzene, toluene, hexanes and cyclohexane are typical hydrocarbon solvents and dichloromethane and dichloroethane are representative halohydrocarbon solvents. In those cases wherein the product is isolated as the acid addition salt, the free base is obtained by techniques known to those skilled in the art. Specifically, an appropriately substituted β-tetralone (I) is reacted with a secondary amine such as pyrrolidine in an inert halohydrocarbon solvent such as, for example, dichloromethane or a hydrocarbon solvent such as benzene for example, under Dean-Stark conditions (removal of water) or in an ethereal solvent such as tetrahydrofuran or an alcohol solvent such as methanol, at a temperature ranging from ambient temperature to reflux, to afford enamine (II). Cyanomethylation of enamine (II) is accomplished by reaction with an α- haloacetonitrile, such as bromoacetonitrile, in an inert solvent such as acetonitrile, at a temperature ranging from ambient temperature to reflux, to afford the iminium salt (III). The iminium salt is hydrolyzed by treatment with an aqueous acid solution, such as hydrochloric or acetic acid, which may contain an organic solvent such as an alcohol or dioxane to facilitate dissolution and reaction, to afford the α- cyanomethyl-β-tetralone (IV). Reductive amination and concomitant cyclization of tetralone (IV) is accomplished by reaction with a reducing agent such as, for example, sodium cyanoborohydride, and an ammonium equivalent such as, for example, ammonium acetate, in an alcohol solvent such as methanol or in a halohydrocarbon solvent such as dichloromethane, at a temperature ranging from ambient temperature to reflux. An organic acid, such as acetic acid for example, may be added to facilitate this transformation; cyclization under these reaction conditions typically affords the c/s-amidine (V) as the major product. Amidine (V) may be converted to its acid addition salt upon treatment with organic acids such as trifluoroacetic acid, or via treatment with inorganic acids such as hydrochloric acid, to afford the corresponding amidine salt (VI) (Scheme 1 ). HX in Scheme 1 represents the hydrochloride salt.
Figure imgf000030_0001
Scheme 1
The amidine products described above ((V) and (VI)) are acylated via suitable amidation methods (see Gross and Meienhofer, Eds., "The Peptides", Vols. 1-3, Academic Press, New York, NY, 1979-1981 ). A carboxylic acid is converted to an activated ester via peptide coupling methods known to those skilled in the art, and the product of this reaction is subsequently reacted with amidine (V) or (VI) to afford the corresponding amide product. For example, trans-4-
(benzenesulfonamido)methylcyclohexane carboxylic acid is reacted with HBTU (2- (1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate and amidine (VI) in the presence of a base such as diisopropylethylamine, in an inert solvent such as N,N-dimethylformamide, at a temperature from ambient temperature to reflux, to afford sulfonamides (VII) of formula A in which Y = carbonyl and Z = (aryl)sulfonamido (Scheme 2). Reaction of amidine (VI) or (V) with alkyl- or heteroaryl- sulfonyl halides, under similar conditions, affords sulfonamides (VIII) of formula A. During these transformations, minor amounts of regiomers (IX) and (X) are formed respectively; compounds of this type are considered to be part of this invention as well.
Figure imgf000031_0001
pep i e coup ing
Figure imgf000031_0002
Figure imgf000031_0003
Figure imgf000031_0004
(VIII)
Scheme 2
Alternatively, a sulfonamido-carboxylic acid is first treated with an amine base, such as triethylamine, in an inert hydrocarbon, ethereal or halohydrocarbon solvent, such as dichloroethane, and subsequently reacted with isobutyl chloroformate at a temperature from about -20°C to 80°C. This resulting mixture is then reacted with amidine (V), in a suitable inert solvent such dichloromethane at a temperature from about -20°C to reflux, to afford the sulfonamides (VII) and (VIII) of formula A respectively, in which Y = carbonyl and Z = (aryl)sulfonamido or sulfonamido.
The amidino sulfonamides of formula A in which Y = methylene are prepared via reduction of amidino amides (VII) and (VIII) by reaction with a suitable reducing agent such as borane-tetrahydrofuran complex or lithium aluminum hydride in an inert hydrocarbon solvent such as toluene or ethereal solvent such as tetrahydrofuran, at a temperature from ambient temperature to reflux. The crude product is treated with an aqueous acid solution such as hydrochloric acid (3M-6M) in order to cleave any boron complexes; neutralization affords sulfonamides (XI) and (XII) as corresponding free bases. Preferably, these materials are isolated as an acid addition salts upon treatment with a suitable organic acid such as thfluoroacetic acid or inorganic acid such as hydrochloric acid (Scheme 3).
Figure imgf000032_0001
Scheme 3
Reduction of the regiomeric amides (IX) and (X) by the methods described above in Scheme 3, affords amines (XIII) and (XIV) (Scheme 4).
Figure imgf000032_0002
Figure imgf000032_0003
(XIV) Scheme 4
Compounds of formula A in which Z = 2,3-dihydro-2-oxo-1H-benzimidazol-1- yl and L = (N-methylene)piperidin-4-yl are prepared from amidines (V) or (VI) and [4- (2-keto-1-benzimidazolinyl)pipehdin-1-yl]acetic acid. For example, 4-(2-keto-1- benzimidazolinyl)piperidine is reacted with a bromoacetic acid ester, such as ethyl bromoacetate, in the presence of an amine base, such as diisopropylethylamine, in an inert solvent such as acetonitnle, at a temperature ranging from ambient temperature to reflux, to afford ethyl [4-(2-keto-1-benzimidazolinyl)piperidin-1- yljacetate. This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an alcoholic solution such as aqueous methanol, to yield, upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, [4-(2-keto-1-benzimidazolinyl)piperidin-1- yljacetic acid. This carboxylic acid is reacted directly with amidine (V) or (VI), in the presence of an amine base, under peptide coupling conditions described above, to afford amidino benzimidazolinones (XV) of formula A in which Y = carbonyl and L = (N-methylene)piperidin-4-yl (Scheme 5).
Figure imgf000034_0001
peptide coupling (e.g. HBTU) / base
Figure imgf000034_0002
Scheme 5
Compounds (XVI) of formula A in which Y = methylene and L = (N- methylene)piperidin-4-yl and Z = 2,3-dihydro-2-oxo-1 H-benzimidazol-1-yl are prepared by reduction of amides (XV) with a reducing agent such as borane- tetrahydrofuran complex or lithium aluminum hydride as described above (Scheme 6).
Figure imgf000035_0001
Scheme 6
Compounds of formula A in which Y = carbonyl, L = (Λ/-methylene)piperazin- 4-yl and Z = phenyl are prepared by reacting a phenylpiperazine with a haloacetic acid ester, such as, for example, ethyl bromoacetate, in the presence of an amine base, such as diisopropylethylamine, in an inert solvent such as acetonitrile, at a temperature ranging from ambient temperature to reflux, to afford ethyl (4- arylpiperazin-1-yl)acetate. This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an aqueous methanol, to yield, upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, (4-arylpiperazin-1-yl)acetic acid. This carboxylic acid is reacted directly with amidine (V) or (VI) in the presence of a base, such as triethylamine for example, under peptide coupling conditions described above, to afford arylpipehdines (XVII) of formula A in which Y = carbonyl, L = (Λ/- methylene)piperazin-4-yl and Z = aryl or substituted aryl (Scheme 7).
Figure imgf000036_0001
peptide coupling (e.g. HBTU) / base
Figure imgf000036_0002
(XVII)
Scheme 7
Compounds (XVIII) of formula A in which Y = methylene, L = (N- methylene)piperazin-4-yl and Z = aryl are prepared by reduction of amides (XVII) with a reducing agent such as borane-tetrahydrofuran complex or lithium aluminum hydride (Scheme 8). Replacement of (4-arylpiperazin-1-yl)acetic acid with a (4- arylpiperidin-1-yl)acetic acid in Schemes 7 and 8 affords compounds of formula A in which L = (Λ/-methylene)piperidin-4-yl and Z = aryl.
Figure imgf000037_0001
(XVII)
1 ) [RED] (e.g., BH3-THF)
2) H
Figure imgf000037_0002
(XVIII)
Scheme 8
Compounds of formula A in which Y = carbonyl, L = (Λ/-methylene)piperidin- 4,4-diyl and Z = 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl are prepared by reacting 1-aryl-1 ,3,8-triazaspiro-[4,5]decan-4-one with a haloacetic acid ester, such as ethyl bromoacetate, in the presence of an amine base, such as diisopropylethylamine, in an inert solvent such as acetonitnle, at a temperature from ambient temperature to reflux, to afford ethyl (1-aryl-1 ,3,8-triazaspiro-[4,5]decan-4-one-8-yl)acetate. This ester is subjected to hydrolysis under basic conditions, for example, by treatment with sodium hydroxide in an alcoholic solution such as aqueous methanol, to yield upon acidification with an inorganic or organic acid such as hydrochloric or acetic acid for example, (1-aryl-1 ,3,8-triazaspiro-[4,5]decan-4-one-8-yl)acetic acid. This carboxylic acid is reacted directly with amidine (V) or (VI), in the presence of a base such as triethylamine for example, under peptide coupling conditions described above, to afford amides (XIX) of formula A in which Y = carbonyl, L = (N- methylene)piperidin-4,4-diyl and Z = 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl (Scheme 9).
Figure imgf000038_0001
(XIX) Scheme 9
Other compounds of this invention having the formula A can be prepared using the methods described herein; modifications of the experimental protocols described above are known or obvious or within the ability of those skilled in the art. For example, a variety of β-tetralones are known or readily prepared by reaction of phenylacetic acids with ethylene gas in the presence of a Lewis acid (for example, Stjemlof, P. et. al. J. Med. Chem. 1995, 38, 2202). Compounds in which the R, group(s) is varied are obtained using this chemistry; in some cases, protecting group manipulations are used and these are obvious or known to those skilled in the art. Examples include masking an amine group as a carbamate, amide or phthalamide, and masking an hydroxyl group as an ether or ester. Other R, substituents are available through (other) functional group manipulations such as, for example, reduction of a nitro group to an amine or dehydration of an amide to a nitrile.
Compounds in which the L group is varied, are derived from amino-carboxylic acids or piperazines or piperidines; hundreds of such compounds are commercially available and many more are known. Compounds of formula A where Z = sulfonamido or (aryl)sulfonamido, in which either the R3 or the R4 group is varied, are accessible by sulfonylation; there are hundreds of sulfonyl halides or sulfonic acids that are commercially available and more that are known. Compounds of formula A where Z = sulfonamido or (aryl)sulfonamido, in which the R3 substituent is heteroaryl can be prepared by substituting a pyridinyl, thienyl or furyl sulfonylchloride for a benzenesulfonamide as described in Scheme 2. N- alkylimidazolylsulfonyl chlorides can be used to prepare sulfonamides of formula A in which the R3 substituent is imidazolyl. Similarly, alkylsulfonyl and cycloalkylsulfonyl halides, alone or in the presence of an activating agent such as a Lewis acid, can be used to prepare sulfonamides of formula A in which the R3 substituent is alkyl or cycloalkyl respectively.
Compounds of formula A with L groups other than methylene are prepared by substituting bromoacetic acid esters with other Ω-bromo acid esters in Schemes 5, 7 and 9. There are hundreds of Ω-bromo acids and esters that are either commercially available or known. Compounds of formula A in which the L group is alkylene are derived from arylalkylenecarboxylic acids; many compounds of this structural type are either commercially available or known. Similarly, arylalkenylene- , arylalkynylene- and arylcycloalkylene- carboxylic acids are known or available and can be used to make compounds of formula A in which L is alkenylene, alkynylene or cycloalkylene respectively.
Compounds in which B2 is other than hydrogen are made starting from an appropriate α-methylated-β-tetralone and carrying out the chemistry described in
Scheme 1 and subsequent schemes and examples. Compounds in which R2 is other than hydrogen are made by reaction of a cyclic amidine with an alkylation agent such as methyl iodide. EXAMPLES
The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it. All compounds were identified by a variety of methods including nuclear magnetic resonance spectroscopy, mass spectrometry and in some cases, infrared spectroscopy and elemental analysis. Nuclear magnetic resonance (300 MHz NMR) data are reported in parts per million downfield from tetramethylsilane. Mass spectra data are reported in mass/charge (m/z) units. Unless otherwise noted, the materials used in the examples were obtained from readily available commercial sources or synthesized by standard methods known to those skilled in the art.
EXAMPLE 1
frans^-[[(Phenylsulfonyl)amino]methyi]-Λ/-(c/s-3a,4,5,9b-tetrahydro-7-methoxy- 1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (7).
1 -(3,4-Dihydro-6-methoxynaphthalen-2-yl)-pyrrolidine (2). A solution of 6-methoxy-3,4-dihydro-1 H-naphthalen-2-one (1 ) (5.64 g, 32 mmol) in methanol (60 mL) was treated with pyrrolidine (3.5 mL, 41.6 mmol) and the resultant mixture was stirred at ambient temperature for 1.5 h. The product precipitated from solution within minutes of the addition of pyrrolidine. The resultant suspension was cooled in an ice bath and the enamine product (2) was collected by filtration as a white solid (5.6 g, 76 %). NMR (CDCI3): δ 1.86-1.94 (m, 4 H), 2.46 (t, 2H), 2.80 (t, 2 H), 3.19-3.25 (m, 4 H), 3.77 (s, 3 H), 5.10 (s, 1 H), 6.59-6.65 (m, 2 H) and 6.78 (d, 1 H).
1 -[1 -(Cyanomethyl)-3,4-dihydro-6-methoxy-2(1 H)-naphthalenylidene)] pyrrolidinium bromide (3).
A solution of 1-(3,4-dihydro-6-methoxynaphthalen-2-yl)-pyrrolidine (2) (5.6 g, 24.4 mmol) in acetonitnle (60 mL) was treated with bromoacetonitrile (2.21 mL, 31.7 mmol). The resultant solution was stirred at ambient temperature for 1 h. The pyrrolidinium salt (3), was collected by filtration and washed with diethyl ether, to give the pyrrolidinium bromide as a hygroscopic colorless solid which was used directly in the subsequent reaction. MS 269 (M+).
(1 ,2,3,4-Tetrahydro-6-methoxy-2-oxo-naphthalen-1 -yl)-acetonitrile (4).
A solution of 1-[1-(cyanomethyl)-3,4-dihydro-6-methoxy-2(1 -/)-naphthalenylidene)] pyrrolidinium bromide (3) (24.4 mmol) and acetic acid (5 mL) in dichloromethane/ methanol/ water (60 mL/ 100 mL/ 50 mL) was stirred at ambient temperature for 18 h. An organic layer was separated and the aqueous layer was extracted with dichloromethane (100 mL). The combined organics were washed with water, then washed with a saturated solution of aqueous sodium bicarbonate, and dried over magnesium sulfate. The solvent was evaporated in vacuo to give the α-cyano-β- tetralone product (4) as a brown oil (3.3 g, 63%, 2 steps). IR(neat): 1715, 1722, 2251 cm 1; NMR(CDCI3): δ 2.47-2.58 (m, 1 H), 2.67-2.80 (m, 1 H), 2.88-3.13 (m, 4 H), 3.77 (t, 1 H), 3.77 (s, 3 H), 6.81-6.90 (m, 2 H), 7.19 (d, 1 H).
3a,4,5,9b-Tetrahydro-7-methoxy-1 H-benzo[e]indol-2-yl)-amine (5) and 3a,4,5,9b-tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl)-amine hydrochloride (6). A solution of (1 ,2,3,4-tetrahydro-6-methoxy-2-oxo-naphthalen-1-yl)-acetonitrile (4) (3.5 g, 16.2 mmol) and ammonium acetate (18.8 g, 0.24 mol) in methanol (50 mL) was stirred at ambient temperature for 15 min. Sodium cyanoborohydride (5.11 g, 0.081 mol) was added and the resultant solution was heated at reflux for 1 h. The solvent was evaporated in vacuo, and the residue was treated with a solution of sodium hydroxide (12 g, 0.3 mol) in water (100 mL) at 0°C. A pale gray solid precipitated out of solution and was collected by filtration, washed with water and triturated in diethyl ether to give the crude cyclic amidine (5) (3.5 g, 100%). This material (3.0 g, 13.8 mmol) was dissolved in tetrahydrofuran/methanol (-9:1 , 75 mL) and treated with 1 M hydrochloric acid in diethyl ether (40 mL) at 0°C to induce precipitation. The resultant precipitate was collected by filtration and washed with diethyl ether to give 3a,4,5,9b-tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl)-amine hydrochloride (6) (1.57 g, 45%) as an off white solid. IR(KBr): 1611 , 1681 , 1703, 2832, 3106 cm"1; NMR(DMSO-d6): δ 1.79-1.91 (m, 2 H), 2.60-2.74 (m, 3 H), 3.33- 3.46 (m, 1 H), 3.63-3.73 (m, 1 H), 3.71 (s, 3 H), 6.80 (d, 1 H), 6.71 (d of d, 1 H), 7.17 (d, 1 H), 9.08 (br s, 1 H), 9.34 (br s, 1 H) and 10.06 (br s, 1 H); MS 217 (M+H)+. (Figure 1 ).
Figure imgf000042_0001
Figure 1
frans^-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro-7-methoxy- 1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (7).
A solution of frans-4-(benzenesulfonamido)methylcyclohexane carboxylic acid (1.16 g, 4.15 mmol), O-benzotriazol-1-yl-/V,/V,/V',/V-tetramethyluronium hexafluorophosphate (1.58 g, 4.15 mmol) and Λ/,Λ/-diisopropylethylamine (2.41 mL,
13.8 mmol) in Λ/,/V-dimethylformamide (15 mL) was stirred at ambient temperature for 15 min. After this time, 3a,4,5,9b-tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl)- amine hydrochloride (6) (1.0 g, 3.96 mmol) was added, and the resultant solution was heated to 45°C for 1.5 h. The solution was then poured into ice water and the product which precipitated was collected by filtration, washed with water and air dried. This solid was triturated in diethyl ether to give frans-4-
[[(phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro-7-methoxy-1 H- benz[e]indol-2-yl)cyclohexanecarboxamide (7) as a colorless solid (1.87 g, 95%). NMR (DMSO-d6): δ 0.69-0.89 (m, 2 H), 1.10-1.34 (m, 3 H), 1.63-1.88 (m, 5 H), 2.10-
2.27 (m, 1 H), 3.24-3.50 (m, 3 H), 3.70 (s, 3 H), 4.04-4.13 (m, 1 H), 6.63 (d, 1 H), 6.74 (d of d, 1 H), 7.05 (d, 1 H), 7.54-7.67 (m, 4 H) and 7.74-7.83 (m, 2 H); MS 496 (M+H)+. (Figure 2).
EXAMPLE 2
Λ/-[[frans-4-[[(c/s-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl) amino]methyl]cyclohexyl]methyl]benzenesulfonamide (8). frat7s-4-[[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/'s-3a,4,5,9b-tetrahydro-7-methoxy-1/-/- benz[e]indol-2-yl]cyclohexanecarboxamide (7) (1.6 g, 3.22 mmol) was added in portions, with stirring, to a solution of lithium aluminum hydride (16.1 mmol) in tetrahydrofuran (36 mL) at ambient temperature. The resultant solution was heated at reflux for 45 min. The solution was then cooled on an ice bath, and then a solution of water (0.65 mL) in tetrahydrofuran (5 mL) was carefully added, followed by the addition of ten percent aqueous sodium hydroxide (0.65 mL) and water (2.1 mL). The resultant suspension, which formed, was stirred at ambient temperature for 30 min and then dried over sodium sulfate. The insoluble inorganic material was removed by filtration, and washed generously with tetrahydrofuran. The solvent was evaporated in vacuo, the residue was dissolved in a minimum amount of isopropanol and this solution was treated with a concentrated solution of hydrogen chloride in isopropanol. The solvents were evaporated in vacuo to give crude give Λ/-[[trans-4- [[(cis-3a,4,5,9b-tetrahydro-7-methoxy-1 H-benz[e]indol-2-yl)amino]methyl] cyclohexyl]methyl]benzenesulfonamide hydrochloride salt as a pale pink solid (1.38 g; estimated purity -75% by HPLC). A 300 mg. portion of this material was purified by preparative HPLC on a C18 reverse phase column (4 cm by 45 cm), eluted with a gradient of water/acetonitrile/trifluoroacetic acid from 90/10/0.1 to 10/90/0.1 (v/v) (flow rate of 40 mL per minute) over 50 minutes. The product obtained was converted to the hydrochloride salt with ethanolic hydrogen chloride to give pure give Λ/-[[ t-a/?s-4-[[(c/'s-3a,4,5,9b-tetrahydro-7-methoxy-1/-/-benz[e]indol-2-yl)amino]methyl] cyclohexyl]methyl]benzenesulfonamide hydrochloride (8) as a colorless solid (0.15 g). NMR (DMSO-d6): δ 0.70-0.94 (m, 4 H), 1.20-1.50 (m, 2 H), 1.62-1.77 (m, 4 H), 1.80-1.94 (m, 2 H), 2.55-2.73 (m, 5 H), 3.03-3.16 (m, 2 H), 3.31-3.46 (m, 1 H), 3.63- 3.73 (m, 1 H), 3.71 (s, 3 H), 4.24-4.32 (m, 1 H), 6.70 (d, 1 H), 6.79 (d of d, 1 H), 7.14 (d, 1 H), 7.55-7.67 (m, 4 H), 7.74-7.82 (m, 2 H), 9.66 (br t, 1 H) and 10.09 (br s, 1 H); MS 482 (M+H)+. (Figure 2).
Figure imgf000044_0001
Figure 2
EXAMPLE 3
frans-4-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro-7-hydroxy- 1H-benz[e]indol-2-yl)cyclohexanecarboxamide (9).
A suspension of frans-4-[[(phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro- 7-methoxy-1H-benz[e]indol-2-yl)cyclohexanecarboxamide (7) (0.200 g, 0.403 mmol) in dichloromethane (2 mL) was added dropwise with stirring, to a solution of boron tribromide (1.6 mmol) in dichloromethane (12 mL) at 0°C. The resultant suspension was stirred at 0°C for 30 min. Methanol (-1 mL) was added at which point the mixture became a clear yellow solution. The solution was stirred for 30 min at 0°C. The solvents were evaporated in vacuo, and the residue was purified by preparative HPLC on C18 reverse phase column, using water/acetonitrile/t fluoroacetic acid (50:50:0.1 ) as the eluent. The product obtained was dissolved in a minimum amount of methanol and converted to the hydrochloride salt by treatment with ethanolic hydrogen chloride. The solvents were evaporated in vacuo and the residue was triturated with diethyl ether to give frans-4-[[(phenylsulfonyl)amino]methyl]-Λ/-(c/s- 3a,4,5,9b-tetrahydro-7-hydroxy-1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (9) as a beige solid (0.093 g, 45%). NMR (DMSO-d6): δ 0.77-0.95 (m, 2 H), 1.20-1.37 (m, 3 H), 1.64-1.80 (m, 2 H), 1.83-1.98 (m, 3 H), 2.43-2.64 (m, 5 H), 2.91 (d of d, 1 H), 3.48-3.74 (m, 4 H), 4.37-4.47 (m, 1 H), 6.54 (d, 1 H), 6.65 (d of d, 1 H), 7.03 (d, 1 H), 7.53-7.83 (m, 6 H), 9.37 (br s, 1 H), 11.56 (br s, 1 H), 13.22 (br s, 1 H); MS 482 (M+H)+ (Figure 3).
Figure imgf000045_0001
Figure 3
EXAMPLE 4
V-[[frans-4-[[(c/s-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl) amino]methyl]cyclohexyl]methyl]benzenesulfonamide hydrochloride (10). A solution of boron tribromide (3.4 mmol) in dichloromethane (3.4 mL) was added to a solution of Λ/-[[frat7S-4-[[(c s-3a,4,5,9b-tetrahydro-7-methoxy-1 H-benz[e]indol-2- yl)amino]methyl]cyclohexyl]methyl]benzenesulfonamide hydrochloride (8) (0.37 g, 0.714 mmol) and triethylamine (0.235 mL, 1.69 mmol) in dichloromethane (20 mL) at 0°C. The resultant mixture was stirred at 0°C for 1 h, and stirring was continued at room temperature for an additional 1 h. The mixture was cooled on an ice bath and methanol was added. After stirring for several minutes, the solvents were evaporated in vacuo. The residue was purified by preparative HPLC on a C18 reverse phase column, eluted with water/acetonitrile/trifluoroacetic acid (-50:50:0.1 ). The product was dissolved in a minimum amount of methanol and converted to the hydrochloride salt with ethanolic hydrogen chloride. The solvents were evaporated in vacuo to give Λ/-[[frans-4-[[(c/s-3a,4,5,9b-tetrahydro-7-hydroxy-1 H-benz[e]indol-2- yl)amino]methyl]cyclohexyl]methyl]benzenesulfonamide hydrochloride as a colorless solid (0.15 g, 42%). NMR (DMSO-d6): δ 0.67-0.98 (m, 4 H), 1.21-1.50 (m, 2 H), 1.58- 1.97 (m, 6 H), 2.50-2.75 (m, 5 H), 3.03-3.23 (m, 2 H), 3.31-3.46 (m, 1 H), 3.55-3.67 (m, 1 H), 4.17-4.33 (m, 1 H), 6.53 (s, 1 H), 6.64 (d, 1 H), 6.99 (d, 1 H), 7.52-7.83 (m, 6 H), 9.34 (br s, 1 H), 9.76 (br s, 1 H) and 10.24 (br s, 1 H); MS 468 (M+H)+ (Figure 4).
Figure imgf000046_0001
Figure 4 EXAMPLE 5
2-[[4-(2,3-Dihydro-2-oxo-1 W-benzimidazol-1 -yl)-1 -piperidinyl]acetyl]- 3a,4,5,9b- tetrahydro-1 H-benzo[e]indol-2-yl)-amine (11 ).
A solution of 4-(2-keto-1-benzimidazolinyl)piperidine (10.0 g, 46 mmol), ethyl bromoacetate (5.1 mL, 46 mmol) and Λ/,Λ/-diisopropylethylamine (8.8 mL, 50.6 mmol) in acetonitnle (200 mL) was heated at reflux for 1 hour. The solvent was evaporated in vacuo, and the residue was suspended in water (-200 mL). The suspension was made basic with the addition of a saturated aqueous solution of sodium bicarbonate. The resultant solid was collected by filtration, washed with water and dried in vacuo to give the ethyl (4-(2-keto-1-benzimidazolinyl)piperidin-1- yl)acetate as a colorless solid (13.2 g, 94%). MS t77/z 304 (MH+); NMR(CDCI3): δ 1.32 (t, 3 H), 1.84 (br d, 2 H), 2.40-2.66 (m, 4 H), 3.13 (br d, 2 H), 3.31 (s, 2 H), 4.23 (q, 2 H), 4.45-4.49 (m, 1 H), 6.99-7.10 (m, 2 H), 7.12-7.19 (m, 1 H), 7.27-7.34 (m, 1 H) and 10.54 (br s, 1 H).
A solution of ethyl (4-(2-keto-1-benzimidazolinyl)piperidin-1-yl)acetate (13.0 g, 42.8 mmol) in methanol (150 mL) was treated with an aqueous solution of sodium hydroxide (3 N, 30 mL, 90 mmol) and heated at reflux for 2 hours. The solution was cooled to room temperature and neutralized with the addition of concentrated hydrochloric acid (12 N, 7.5 mL). The solvent was evaporated in vacuo, and the resultant amorphous solid was dried in vacuo with heating (~50°C) overnight to give (4-(2-keto-1-benzimidazolinyl)piperidin-1-yl)acetic acid (17.2 g) which was used in the subsequent step without purification. MS m/z 304 (MH+); NMR(DMSO-d6): δ 1.74 (br d, 2 H), 2.53-2.67 (m, 2 H), 2.74-2.86 (m, 2 H), 3.33 (s, 2 H), 4.29-4.42 (m, 1 H), 6.97-7.05 (m, 3 H) and 7.38-7.43 (m, 1 H).
A mixture of (4-(2-keto-1-benzimidazolinyl)piperidin-1-yl)acetic acid (2.34 g, -5.83 mmol), 2-(1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyuronium hexafluorophosphate (1.87 g, 4.93 mmol) and Λ/,Λ/-diisopropylethylamine (3.1 mL, 17.9 mmol) in N,N- dimethylformamide (15 mL) was stirred at 45°C for 10 min. After this time, 3a,4,5,9b-tetrahydro-1H-benzo[e]indol-2-yl)-amine (1.0 g, 4.49 mmol) was added to the mixture, and the resultant solution was stirred at room temperature for an additional two hours. A white precipitate was collected by filtration and washed with water. The product was purified by flash chromatography on silica gel using 5 to 10% methanol in dichloromethane as the eluent. The product was triturated with diethyl ether and dried in vacuo to give 2-[[4-(2,3-dihydro-2-oxo-1 H-benzimidazol-1- yl)-1-piperidinyl]acetyl]-3a,4,5,9b-tetrahydro-1H-benzo[e]indol-2-yl)-amine (11 ) as a colorless solid, (0.23 g, 9%). An additional 0.6 g of product was recovered from the mother liquor as well as several impure fractions of the chromatography. MS m/z 444 (MH+); NMR(CDCI3): δ 1.78-2.10 (m, 4 H), 2.34-2.83 (m, 6 H), 3.00-3.17 (m, 3 H), 3.20 (s, 2 H), 3.56-3.78 (m, 2 H), 4.27-4.45 (m, 2 H) and 7.00-7.23 (m, 8 H). (Figure 5).
Figure imgf000048_0001
HBTU) / base
Figure imgf000048_0002
EXAMPLE 6
2-[[4-(2,3-Dihydro-2-oxo-1 H-benzimidazol-1 -yl)-1 -piperidinyl]ethyl]- 3a,4,5,9b- tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl)-amine (12).
2-[[4-(2,3-Dihydro-2-oxo-1 H-benzimidazol-1 -yl)-1 -piperidinyl]acetyl]-3a,4,5,9b- tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl)-amine (0.500 g, 1.13 mmol) was carefully added in portions, with stirring, to a solution of lithium aluminum hydride (4.0 mmol) in tetrahydrofuran (20 mL). Considerable foaming occurred with each addition. The resultant mixture was heated at reflux for 1.5 hours. The resultant solution was cooled on an ice bath, and a solution of water (0.16 mL) in tetrahydrofuran (5 mL) was carefully added, with stirring, to the solution. With care, 15% aqueous sodium hydroxide (0.16 mL) was added followed by the addition of another aliquot of water (0.5 mL). The inorganic salts were removed by filtration and washed successively with tetrahydrofuran and dichloromethane. The organic solutions were combined, and the solvents were evaporated in vacuo. The residue was purified by preparative HPLC on a C18 reverse phase column eluted with a gradient of acetonitrile/water/trifluoroacetic acid from 10/90/0.1 (v/v) to 90/10/0.1 to give 2-[[4-(2,3-dihydro-2-oxo-1 /-/-benzimidazol-1 -yl)-1 -piperidinyl]acetyl]-3a,4,5,9b- tetrahydro-7-methoxy-1 /-/-benzo[e]indol-2-yl)-amine (12) as a thfluoroacetic acid salt, (0.166 g, 29%). MS m/z 430 (MH+); NMR(DMSO-d6): δ 1.86-2.03 (m, 4 H), 2.58- 2.83 (m, 4 H), 3.15-3.87 (m, 11 H), 4.33-4.45 (m, 1 H), 4.47-4.60 (m, 1 H), 6.94-7.04 (m, 3 H), 7.11-7.38 (m, 5 H), 10.03 (br s, 1 H), 10.41 (br s, 1 H) and 10.98 (br s, 1 H). (Figure 6).
Figure imgf000050_0001
The following compounds of this invention were prepared from appropriately substituted β-tetralones as the starting material using the experimental protocols described above.
(rans-4-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro-1H- benz[e]indol-2-yl)cyclohexanecarboxamide (13). Calculated mass: 465; MS: 466 (M+H)+
Λ/-[[frans-4-[[(c/'s-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2- yl)amino]methyl]cyclohexyl]methyl]benzenesulfonamide (14). Calculated mass: 451 ; MS: 452 (M+H)+
fra/ιs-4-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/'s-3a,4,5,9b-tetrahydro-7 -fluoro- 1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (15). Calculated mass: 483; MS: 484 (M+H)+
Λ/-[[frans-4-[[(c/s-3a,4,5,9b-tetrahydro-7-fluoro-1H-benz[e]indol-2- yl)amino]methyl]cyclohexyl]methyl]benzenesulfonamide (16).
Calculated mass: 469; MS: 470 (M+H)+ frans-4-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/s-3a,4,5,9b-tetrahydro-7-chloro- 1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (17). Calculated mass: 499; MS: 500 (M+H)+
W-[[frans-4-[[(c/s-3a,4,5,9b-tetrahydro-7-chloro-1H-benz[e]indol-2- yl)amino]methyl]cyclohexyl]methyl]benzenesulfonamide (18). Calculated mass: 485; MS: 486 (M+H)+
frans-4-[[(Phenylsulfonyl)amino]methyl]-Λ/-(c/'s-3a,4,5,9b-tetrahydro-7- methoxy-1 H-benz[e]indol-2-yl)cyclohexanecarboxamide (19).
Calculated mass: 513; MS: 514 (M+H)+
2-[[4-(2,3-Dihydro-2-oxo-1 H-benzimidazol-1 -yl)-1 -piperidinyl]acetyl]-[3a,4,5,9b- tetrahydro-7-methoxy-1H-benzo[e]indol-2-yl]-amine (20).
Calculated mass: 473; MS: 474 (M+H)+
2-[[4-(2,3-Dihydro-2-oxo-1 H-benzimidazol-1 -yl)-1 -piperidinyl]acetyl]-[3a,4,5,9b- tetrahydro-7-hydroxy-1 H-benzo[e]indol-2-yl]-amine (21 ). Calculated mass: 459; MS: 460 (M+H)+
IN VITRO ASSAYS
NPY5 HTS Centrifugation Assay
The compounds described in this invention were evaluated for binding to the human neuropeptide Y5 receptor.
Stable Transfection
The human NPY5 receptor cDNA (Genbank Accession number U66275) was inserted into the vector pClneo (Invitrogen) and transfected into human embryonic kidney cells (HEK-293) via calcium phosphate method (Cullen 1987). Stably transfected cells were selected with G-418 (600 μg/mL). Stably transfected cells served as the source for the membranes for the NPY5 receptor binding assay.
Membrane Preparation
NPY5-transfected HEK293 cells were grown to confluence in 150 cm2 culture dishes. Cells were washed once with phosphate-buffered saline (Gibco Cat# 14040-133). Cells were then incubated in phosphate-buffered saline without calcium and without magnesium, supplemented with 2 mM EDTA. Cells were incubated for 10 minutes at room temperature and the cells were collected by repetitive pipeting. Cells were formed into pellets and then frozen at -80°C until needed. Frozen pellets were homogenized with a polytron at full speed for 12 seconds in a homogenization buffer (20 mM Tris HCI, 5 mM EDTA, pH 7.4). Homogenates were centrifuged for 5 minutes at 4° C at 200g. Supernatants were transferred to corex tubes and centrifuged for 25 minutes at 28,000g. Pellets were re-suspended in Binding (20mM HEPES, 10 mM NaCI, 0.22 mM KH2PO4, 1.3mM CaCl2, 0.8 mM MgSO4, pH 7.4). Membranes were kept on ice until use.
A competition binding assay, known to those skilled in the art, was used in which compounds of formula A compete with 25I-PYY for binding to cell membranes. In simple terms, the less 125I-PYY bound to the membranes implies that a compound is a good inhibitor (competitor). Bound 5I-PYY is determined by centrifugation of membranes, aspirating supernatant, washing away residual 125l- PYY and subsequently counting the bound sample in a g-counter.
Procedure for Radioligand binding assay
Compounds to be tested were prepared as 10x stocks in binding buffer and added first to assay tubes (RIA vials, Sarstedt). Twenty (20) μL of each 10x compound stock is pipeted into vials and 80 μL of 125I-PYY (NEN catalog number NEX240), which has been diluted to a concentration of 200 pM in 0.25 % BSA in binding buffer, is added to the compound tubes (final concentration of 25I-PYY is 80 pM). To each tube is added 100 μL of membranes and the mixture is agitated by pipeting 2 times. Samples are incubated for 1 hr at room temperature. Aluminum cast plates (Sarstedt) containing the vials are then centrifuged 10 minutes at 3200 rpm in a Sorvall RT6000. Supernatant is then aspirated. To each vial 400 μL PBS is added and this is then aspirated again. Vials are then put in carrier polypropylene 12x75 tube and counted in gamma counter (Packard). Non-specific binding is determined in the presence of 300 nM NPY. Percent inhibition of 125I-PYY binding is calculated by subtracting non-specific binding from the test samples (compound (I)), taking these counts and dividing by total binding, and multiplying by 100. Inhibitory concentration values (IC50) of compounds that show appreciable inhibition of 125l- PYY binding are calculated by obtaining percent inhibition of 125I-PYY binding values at different concentrations of the test compound, and using a graphing program such as GraphPad Prism (San Diego, CA) to calculate the concentration of test compound that inhibits fifty-percent of 125I-PYY binding (Table 4).
Binding Affinities of Compounds of Formula A for the Human NPY Y5 Receptor (expressed as % Inhibition of 125I-PYY Binding)
Figure imgf000054_0001
Table 1
IN VIVO ASSAYS
Rodent Feeding Model:
Measurement of Food Intake in Food-Deprived Rats
Male Long-Evans rats (180-200 grams) are housed individually and are maintained on a once-a-day feeding schedule (i.e., 10 a.m. until 4 p.m.) for five days following quarantine to allow the animals to acclimate to feeding on powdered chow (#5002 PMI Certified Rodent Meal) during the allotted time. The chow is made available in an open jar, anchored in the cage by a wire, with a metal follower covering the food to minimize spillage. Water is available ad-libitum.
Animals are fasted for 18 hours prior to testing. At the end of the fasting period, animals are administered either compounds of the invention or vehicle. Vehicle and test compounds are administered either orally (5 mL/kg) 60 minutes prior to the experiment, or 30 minutes prior when given subcutaneously (1 mL/kg) or intraperitoneally (1 mL/kg). Compounds of the invention are administered orally as a suspension in aqueous 0.5% methylcellulose-0.4% Tween 80, or intraperitoneally as a solution or suspension in PEG 200; compound concentrations typically range from 1 mg/kg to 100 mg/kg, preferably from 10-30 mg/kg. Food intake is measured at 2, 4, and 6 hours after administration by weighing the special jar containing the food before the experiment and at the specified times. Upon completion of the experiment, all animals are given a one-week washout period before retesting.
Percent reduction of food consumption is calculated subtracting the grams of food consumed by the treated group from the grams of food consumed by the control group divided by the grams of food consumed by the control group, multiplied by 100. A negative value indicates a reduction in food consumption and a positive value indicates an increase in food consumption.
% change = Treatment - Vehicle X 100 Vehicle
Food Consumption (avg. grams)
Compound Dose(mg/kg) 0-2 h 0-4 h 0-6 h 2-6h
# (#ratsϊ .%chq.) (%chα.) (%chα.) (%chq.
Vehicle PEG-2000 N=8 10.19 g 13.71 g 21.03 g 10.84 g
10 30 (i.p.) 4.38 g 6.43 g 10.75 g 6.37 g N=6 (-57%) (-53%) (-49%) (-41%)
Vehicle PEG-2000 N=8 9.13 g 12.75 g 21.25 g 12.13 g
8 10 (i.p.) 4.38 g 7.88 g 12.00 g 7.63 g N=8 (-52%) (-38%) (-43%) (-37%)

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula:
Figure imgf000056_0001
in which
R1 is independently selected from the group consisting of hydrogen; hydroxy; halo; Chalky!; C^alkoxy; substituted C,.8 alkyl wherein the substituent is halo; substituted C,^ alkoxy wherein the substituent is halo; trifluoroalkyl; C^alkylthio and substituted C^alkylthio wherein the substituent is selected from halo, trifluoroalkyl and C^alkoxy; C3.6cycloalkyl; C3.8cycloalkoxy; nitro; amino; C^ealkylamino; C^dialkylamino; C4.8cycloalkylamino; cyano; carboxy;
C^alkylcarbonyloxy; C,_5alkoxycarbonyloxy; formyl; carbamoyl; phenyl; and substituted phenyl wherein the substituent is selected from halo, hydroxyl, nitro, amino and cyano;
n is 0-2;
B2 is selected from the group consisting of hydrogen; C^alkyl; substituted C,.5alkyl wherein the substituent is halo;
B2 may have either a cis- or trans- stereochemical orientation with respect to
Y is methylene (-CH2-) or carbonyl (C=O) is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3_7cycloalkylene;
C^cycloalkylC^alkylene; arylC^alkylene;
(N-methylene)pipehdin-4-yl;
Figure imgf000057_0001
(N-methylene)piperazin-4-yl;
— CHj— N N- and
(N-methylene)piperidin-4,4-diyl;
Figure imgf000057_0002
R2 is independently selected from the group consisting of hydrogen; C^alkyl; substituted C^alkyl wherein the substituent is halo;
_\ is hydrogen;
-\Λ may have either a cis- or trans- stereochemical orientation with respect to B2;
Z is selected from the group consisting of:
phenyl;
Figure imgf000057_0003
N-sulfonamido; o
I I -N— S— R3 I I I 3 H O
N-(aryl)sulfonamido;
Figure imgf000058_0001
2,3-dihydro-2-oxo-1 H-benzimidazol-1 -yl;
Figure imgf000058_0002
and 1 -aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
Figure imgf000058_0003
is selected from the group consisting of C^alkyl; substituted C,.8alkyl wherein the substituent is selected from alkoxy and halo; cycloalkyl; substituted cycloalkyl wherein the substituent is selected from C|_8alkoxy and halo; naphthyl; substituted naphthyl wherein the substituent is selected from halo, nitro, amino and cyano; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl wherein the substituent is selected from halo, nitro, amino and cyano; R4 is independently selected from the group consisting of C^alkyl; alkoxy; hydroxy; halo; cyano, nitro; amino and alkylamino; substituted C,.8alkyl wherein the substituent is halo;
m is 0-2;
with the following provisions:
when L isC,.8alkylene; C2.10alkenylene; C2.10alkynylene; C37cycloalkylene; C^cycloalkyleneC^alkylene; arylC^alkylene; (N-methylene)piperidin-4-yl; then Z is phenyl; N-sulfonamido; N-(aryl)sulfonamido; or 2,3-dihydro-2-oxo-1 H-benzimidazol-1 -yl;
when L is (N-methylene)piperazin-4-yl; then Z is phenyl or aryl; and
when L is (N-methylene)pipehdin-4,4,-diyl; then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.
2. A compound of Claim 1 wherein Ri is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;
B2 and Bi are hydrogen;
R2 is hydrogen or alkyl;
Y is methylene or carbonyl;
L is alkylene, alkenylene, alkynylene, (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl or (N-methylene)pipehdin-4,4-diyl;
Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1 H-benzimidazo- 1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
R3 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R4 is alkyl, alkoxy, hydroxy, halo, cyano, nitro, amino, alkylamino or substituted alkyl;
n is 0-2;
m is 0-2;
provided that when:
L is C-|-8alkylene, C2-I0alkenylene; C2-I 0alkynylene, C3-7cycloalkylene, C3- 7cycloalkyleneCi-4alkylene, arylCι_4alkylene or (N-methylene)pipehdin-4-yl, then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1 H-benzimidazol-1 - yi;
when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and
when L is (N-methylene)pipehdin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo- imidazol-5,5-diyl;
and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
claim 1 selected from the group consisting of:
Figure imgf000061_0001
and d of claim 1 selected from the group consisting of:
Figure imgf000062_0001
f claim 1 selected from the group consisting of:
Figure imgf000063_0001
d of claim 1 selected from the group consisting of:
Figure imgf000064_0001
f claim 1 selected from the group consisting of:
Figure imgf000065_0001
8. A compound of claim 1 selected from the group consisting of:
Figure imgf000066_0001
9. A compound of claim 1 selected from the group consisting of:
Figure imgf000067_0001
0. A compound of claim 1 selected from the group consisting of:
Figure imgf000068_0001
1. A compound of claim 1 selected from the group consisting of:
Figure imgf000069_0001
of claim 1 selected from the group consisting of:
Figure imgf000070_0001
3. A compound of claim 1 selected from the group consisting of:
Figure imgf000071_0001
4. A compound of claim 1 selected from the group consisting of:
Figure imgf000072_0001
15. A compound of the formula:
Figure imgf000073_0001
Wherein
R, is independently selected from the group consisting of hydrogen; hydroxy; halo; C,_8alkyl; C^alkoxy; substituted C^ alkoxy; trifluoroalkyl; C,.8alkylthio; C3.6cycloalkyl; C3.8cycloalkyloxy; nitro; amino; C^alkylamino; C^dialkylamino;
C4_8cycloalkylamino; cyano; carboxy; C^alkylcarbonyloxy; C^
5alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl; n is 0 to 2
R3 is independently selected from the group consisting of C,.8alkyl; substituted C^alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;
L is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3.7cycloalkylene;
C^cycloalkylC^alkylene; arylC^alkylene;
(N- methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;
and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
16. A compound of the formula:
Figure imgf000074_0001
wherein
R, is independently selected from the group consisting of hydrogen; hydroxy; halo; C,_8alkyl; C^alkoxy; substituted C^ alkoxy; trifluoroalkyl; CLgalkylthio;
C3.6cycloalkyl; C3.8cycloalkyloxy; nitro; amino;
Figure imgf000074_0002
C4.8cycloalkylamino; cyano; carboxy; C^alkylcarbonyloxy; C^
5alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;
n is 0 to 2
R4 is independently selected from the group consisting of Chalky!; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted Chalky! wherein the substituent is halo;
L is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3.7cycloalkylene;
C3.7cycloalkylC1Jtalkylene; arylC^alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl; and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
17. A compound of the formula:
Figure imgf000075_0001
Wherein
R is independently selected from the group consisting of hydrogen; hydroxy; halo; C^alkyl; C^alkoxy; substituted C^ alkoxy; trifluoroalkyl; C^alkylthio; C3.6cycloalkyl; C3.8cycloalkyloxy; nitro; amino; C^alkylamino; C^dialkylamino;
C4_8cycloalkylamino; cyano; carboxy; C^alkylcarbonyloxy; C^
5alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl; n is 0 to 2
HX is hydrochloric acid or trifluoroacetic acid
R3 is independently selected from the group consisting of C,.8alkyl; substituted C,.8alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;
L is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3.7cycloalkylene;
C3.7cycloalkylClJ(alkylene; arylC^alkylene;
(N-methylene)pipehdin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl; and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
18. A compound of the formula:
Figure imgf000076_0001
wherein
RT is independently selected from the group consisting of hydrogen; hydroxy; halo; C^alkyl; C^alkoxy; substituted C _e alkoxy; trifluoroalkyl; C^alkylthio; C3.6cycloalkyl; C3.8cycloalkyloxy; nitro; amino;
Figure imgf000076_0002
C4.8cycloalkylamino; cyano; carboxy; C^alkylcarbonyloxy; C^ 5alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;
HX is hydrochloric acid or trifluoroacetic acid n is 0 to 2 R4 is independently selected from the group consisting of C^alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C,.8alkyl wherein the substituent is halo;
L is selected from the group consisting of
C,_8alkylene; C2.10alkenylene; C2.10alkynylene; C3.7cycloalkylene;
C^cycloalkylC^alkylene; arylC^alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl; and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
19. A compound of Claim 1 wherein:
R-| is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;
B2 and Bi are hydrogen;
R2 is hydrogen or alkyl;
Y is methylene or carbonyl;
L is selected from the group consisting of
C^alkylene; C2.10alkenylene; C2.10alkynylene; C3_7cycloalkylene; C3.7cycloalkylClJtalkylene; arylC^alkylene; (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;
Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1 H- benzimidazo-1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;
R3 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R4 is independently selected from the group consisting of C^alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino; alkylamino; and substituted C,.8alkyl wherein the substituent is halo;
n is 0-2;
m is 0-2;
provided that when:
L is Ci-8alkylene, C2-10alkenylene; C2-10alkynylene, C3-7cycloalkylene, C3- 7cycloalkyleneCi_4alkylene, arylCi-4alkylene or (N-methylene)piperidin-4-yl, then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1 H- benzimidazol-1-yl;
when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and when
L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5- diyl;
and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.
20. A method of treating disorders and diseases associated with NPY receptor subtype Y5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
21. A pharmaceutical composition for the treatment of diseases or disorders associated with NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition according to Claim 21 for the treatment of disorders or disease states caused by eating disorders, obesity, anorexia nervosa, bulimia nervosa, diabetes, dyspilipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression or anxiety.
PCT/US2000/010981 1999-05-05 2000-04-20 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS WO2000068197A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA01011321A MXPA01011321A (en) 1999-05-05 2000-04-20 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS.
AU46592/00A AU4659200A (en) 1999-05-05 2000-04-20 3a,4,5,9b-tetrahydro-1h-benz(e)indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
CA002373035A CA2373035A1 (en) 1999-05-05 2000-04-20 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
EP00928340A EP1177172A1 (en) 1999-05-05 2000-04-20 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
HK02102941.4A HK1041263A1 (en) 1999-05-05 2002-04-18 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13266099P 1999-05-05 1999-05-05
US60/132,660 1999-05-05

Publications (1)

Publication Number Publication Date
WO2000068197A1 true WO2000068197A1 (en) 2000-11-16

Family

ID=22455028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010981 WO2000068197A1 (en) 1999-05-05 2000-04-20 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS

Country Status (6)

Country Link
EP (1) EP1177172A1 (en)
AU (1) AU4659200A (en)
CA (1) CA2373035A1 (en)
HK (1) HK1041263A1 (en)
MX (1) MXPA01011321A (en)
WO (1) WO2000068197A1 (en)

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183245A1 (en) * 1999-04-22 2002-03-06 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2002047712A3 (en) * 2000-12-14 2002-09-06 Amylin Pharmaceuticals Inc Peptide yy and peptide yy agonists for treatment of metabolic disorders
US6569856B2 (en) 1999-04-22 2003-05-27 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
US6699891B1 (en) 1999-11-26 2004-03-02 Shionogi & Co., Ltd. Npyy5 antagonists
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
JP2005531571A (en) * 2002-05-23 2005-10-20 アボット・ラボラトリーズ Acetamides and benzamides useful for the treatment of sexual dysfunction
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US7034034B2 (en) 2001-10-23 2006-04-25 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008060476A2 (en) 2006-11-15 2008-05-22 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US7396809B1 (en) 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
WO2009054434A1 (en) 2007-10-25 2009-04-30 Shionogi & Co., Ltd. Amine derivative having npy y5 receptor antagonist activity and use thereof
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
AU2007200224B2 (en) * 2000-12-14 2009-10-01 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2127676A2 (en) 2004-11-01 2009-12-02 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US7723471B2 (en) 2004-02-11 2010-05-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP2330124A2 (en) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
EP2330125A2 (en) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US9139518B2 (en) 2006-04-28 2015-09-22 Shionogi & Co., Ltd. Amine derivative having NPY Y5 receptor antagonistic activity
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
WO1999055667A1 (en) * 1998-04-29 1999-11-04 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO2000020376A1 (en) * 1998-10-07 2000-04-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
WO1999055667A1 (en) * 1998-04-29 1999-11-04 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO2000020376A1 (en) * 1998-10-07 2000-04-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCNALLY J.J. ET AL: "N-(Sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 10, no. 3, February 2000 (2000-02-01), pages 213 - 216, XP004188819, ISSN: 0960-894X *

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396809B1 (en) 1999-02-10 2008-07-08 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US7807641B2 (en) 1999-02-10 2010-10-05 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6569856B2 (en) 1999-04-22 2003-05-27 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
EP1183245A4 (en) * 1999-04-22 2002-10-02 Synaptic Pharma Corp Selective npy (y5) antagonists
US7189720B2 (en) 1999-04-22 2007-03-13 H. Lundbeck A/S Selective NPY (Y5) antagonists
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
EP1183245A1 (en) * 1999-04-22 2002-03-06 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6699891B1 (en) 1999-11-26 2004-03-02 Shionogi & Co., Ltd. Npyy5 antagonists
US8115027B2 (en) 1999-11-26 2012-02-14 Shionogi & Co., Ltd. NPY Y5 antagonist
US7781461B2 (en) 1999-11-26 2010-08-24 Yasuyuki Kawanishi NPY Y5 antagonist
US7265130B2 (en) 1999-11-26 2007-09-04 Shionogi & Co., Ltd. NPY Y5 antagonist
CN1568195B (en) * 2000-12-14 2011-03-02 安米林药品公司 Peptide YY and peptide YY agonists for treatment of metabolic disorders
AU2007200224B2 (en) * 2000-12-14 2009-10-01 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
WO2002047712A3 (en) * 2000-12-14 2002-09-06 Amylin Pharmaceuticals Inc Peptide yy and peptide yy agonists for treatment of metabolic disorders
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US7034034B2 (en) 2001-10-23 2006-04-25 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives
JP2005531571A (en) * 2002-05-23 2005-10-20 アボット・ラボラトリーズ Acetamides and benzamides useful for the treatment of sexual dysfunction
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP2338490A2 (en) 2003-11-03 2011-06-29 Probiodrug AG Combinations Useful for the Treatment of Neuronal Disorders
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8906849B2 (en) 2004-02-11 2014-12-09 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US8426361B2 (en) 2004-02-11 2013-04-23 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
US7723471B2 (en) 2004-02-11 2010-05-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP2286838A2 (en) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP2286840A2 (en) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Treatment of obesity and related diseases
EP2127676A2 (en) 2004-11-01 2009-12-02 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP2286837A2 (en) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Treatment of obesity and obesity related diseases
EP2286839A2 (en) 2004-11-01 2011-02-23 Amylin Pharmaceuticals, Inc. Treatment of obesity and related diseases
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
EP2330124A2 (en) 2005-08-11 2011-06-08 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
EP2330125A2 (en) 2005-08-11 2011-06-08 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US9139518B2 (en) 2006-04-28 2015-09-22 Shionogi & Co., Ltd. Amine derivative having NPY Y5 receptor antagonistic activity
US9150507B2 (en) 2006-04-28 2015-10-06 Shionogi & Co., Ltd. Amine derivative having NPY Y5 receptor antagonistic activity
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008060476A2 (en) 2006-11-15 2008-05-22 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009054434A1 (en) 2007-10-25 2009-04-30 Shionogi & Co., Ltd. Amine derivative having npy y5 receptor antagonist activity and use thereof
US8299265B2 (en) 2007-10-25 2012-10-30 Shionogi & Co., Ltd. Amine derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
EP1177172A1 (en) 2002-02-06
HK1041263A1 (en) 2002-07-05
CA2373035A1 (en) 2000-11-16
MXPA01011321A (en) 2003-08-01
AU4659200A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
WO2000068197A1 (en) 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
EP1202986B1 (en) Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EP1177188B1 (en) Pyrazole carboxamides useful for the treatment of obesity and other disorders
EP1257539B1 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
US6140354A (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6201025B1 (en) N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
US6987188B2 (en) 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2373035

Country of ref document: CA

Ref country code: CA

Ref document number: 2373035

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011321

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 46592/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 515321

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000928340

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000928340

Country of ref document: EP